The Oncology Institute, Inc. Stock

Equities

TOI

US68236X1000

Healthcare Facilities & Services

End-of-day quote Nasdaq 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
1.15 USD -2.54% Intraday chart for The Oncology Institute, Inc. -3.36% -43.63%
Sales 2024 * 413M Sales 2025 * 483M Capitalization 85.46M
Net income 2024 * -50M Net income 2025 * -36M EV / Sales 2024 * 0.21 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.18 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.69%
More Fundamentals * Assessed data
Dynamic Chart
The Oncology Institute, Inc. Appoints Jordan McInerney as New Chief Development Officer CI
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California CI
Transcript : The Oncology Institute, Inc., Q4 2023 Earnings Call, Mar 27, 2024
The Oncology Institute Q4 Loss Widens, Revenue Increases MT
(TOI) THE ONCOLOGY INSTITUTE Forecasts Fiscal Year 2024 Revenue Range $400M - $415M MT
Earnings Flash (TOI) THE ONCOLOGY INSTITUTE Posts Q4 Revenue $85.8M MT
The Oncology Institute, Inc. Provides Earnings Guidance for the Year 2024 CI
The Oncology Institute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
MaxHealth & The Oncology Institute, Inc. Expand Value-Based Care Partnership CI
The Oncology Institute Expands Its Specialty Medication Business by Opening Pharmacy Operations in California CI
Oncology Institute Insider Sold Shares Worth $118,581, According to a Recent SEC Filing MT
Transcript : The Oncology Institute, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Tranche Update on The Oncology Institute, Inc.'s Equity Buyback Plan announced on August 30, 2023. CI
Tranche Update on The Oncology Institute, Inc.'s Equity Buyback Plan announced on June 15, 2023. CI
The Oncology Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
1 day-2.54%
1 week-3.36%
Current month-27.22%
1 month-37.50%
3 months-46.01%
6 months-39.15%
Current year-43.63%
More quotes
1 week
1.12
Extreme 1.12
1.29
1 month
1.12
Extreme 1.12
1.63
Current year
1.12
Extreme 1.12
2.50
1 year
0.33
Extreme 0.33
2.66
3 years
0.33
Extreme 0.33
12.66
5 years
0.33
Extreme 0.33
12.66
10 years
0.33
Extreme 0.33
12.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 18-12-31
Director of Finance/CFO 45 22-04-03
Chief Operating Officer 41 23-09-04
Members of the board TitleAgeSince
Chairman 70 21-11-11
Director/Board Member 68 22-09-20
Director/Board Member 45 18-12-31
More insiders
Date Price Change Volume
24-04-26 1.15 -2.54% 79,351
24-04-25 1.18 -1.67% 58,372
24-04-24 1.2 +1.69% 36,287
24-04-23 1.18 +4.42% 61,406
24-04-22 1.13 -5.04% 111,720

End-of-day quote Nasdaq, April 25, 2024

More quotes
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.15 USD
Average target price
2.5 USD
Spread / Average Target
+117.39%
Consensus

Quarterly revenue - Rate of surprise